Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MediciNova, Inc. MNOV
$2.18
+$0.02 (0.93%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
107901640.00000000
-
week52high
2.77
-
week52low
1.89
-
Revenue
0
-
P/E TTM
-8
-
Beta
0.98650500
-
EPS
-0.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 10 мар 2021 г. | |
| B. Riley FBR | Buy | Buy | 13 мар 2020 г. |
| B. Riley FBR | Buy | 05 мая 2018 г. | |
| B. Riley FBR | Buy | 28 мар 2018 г. | |
| Ladenburg Thalmann | Buy | Buy | 24 мая 2012 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| IWAKI YUICHI | A | 235125 | 235125 | 23 янв 2023 г. |
| Matsuda Kazuko | A | 149625 | 149625 | 23 янв 2023 г. |
| OBrien Geoffrey | A | 76950 | 76950 | 23 янв 2023 г. |
| Nagao Hideki | D | 0 | 6754 | 28 ноя 2022 г. |
| Nagao Hideki | D | 6754 | 218 | 22 ноя 2022 г. |
| Nagao Hideki | D | 6972 | 5365 | 21 ноя 2022 г. |
| Nagao Hideki | D | 12337 | 309 | 17 ноя 2022 г. |
| BEAVER CAROLYN | A | 20000 | 20000 | 16 июн 2022 г. |
| Nagao Hideki | A | 20000 | 20000 | 16 июн 2022 г. |
| IWAKI YUICHI | A | 302500 | 302500 | 27 янв 2022 г. |
Новостная лента
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
GlobeNewsWire
15 сент 2022 г. в 19:00
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.
MediciNova Posts Promising Data From COVID-19 Treatment Candidate
Benzinga
08 июн 2022 г. в 09:15
MediciNova Inc (NASDAQ: MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed. The trial achieved statistical significance for one of the co-.